121 related articles for article (PubMed ID: 11722418)
21. Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation.
Gilman AL; Leung W; Cowan MJ; Cannon M; Epstein S; Barnhart C; Shah K; Hyland M; Fukes T; Ivanova A
Am J Hematol; 2018 Feb; 93(2):169-178. PubMed ID: 29047161
[TBL] [Abstract][Full Text] [Related]
22. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
23. Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience.
El-Cheikh J; Crocchiolo R; Furst S; Ladaique P; Castagna L; Faucher C; Calmels B; Oudin C; Lemarie C; Granata A; Devillier R; Vey N; Bouabdallah R; Chabannon C; Blaise D
Exp Hematol; 2013 Jan; 41(1):17-27. PubMed ID: 23022128
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT.
Urbano-Ispizua A; Solano C; Brunet S; de la Rubia J; Odriozola J; Zuazu J; Figuera A; Caballero D; Martínez C; García J; Sanz G; Torrabadella M; Alegre A; Pérez-Oteiza J; Jurado M; Oyonarte S; Sierra J; García-Conde J; Rozman C
Bone Marrow Transplant; 1998 Sep; 22(6):519-25. PubMed ID: 9758337
[TBL] [Abstract][Full Text] [Related]
25. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
Kanate AS; Craig M; Cumpston A; Saad A; Hobbs G; Leadmon S; Bunner P; Watkins K; Bulian D; Gibson L; Abraham J; Remick SC; Hamadani M
Hematol Oncol Stem Cell Ther; 2011; 4(4):149-56. PubMed ID: 22198185
[TBL] [Abstract][Full Text] [Related]
26. Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease.
Gómez-Almaguer D; Gómez-Peña Á; Jaime-Pérez JC; Gómez-Guijosa MÁ; Cantú-Rodríguez O; Gutiérrez-Aguirre H; Martínez-Cabriales SA; García-Rodríguez F; Olguín-Ramírez LA; Salazar-Riojas R; Méndez-Ramírez N
J Clin Apher; 2013 Oct; 28(5):349-55. PubMed ID: 23682006
[TBL] [Abstract][Full Text] [Related]
27. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
28. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
29. Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants.
Rutella S; Rumi C; Laurenti L; Pierelli L; Sora' F; Sica S; Leone G
Br J Haematol; 2000 Jan; 108(1):105-15. PubMed ID: 10651733
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
[TBL] [Abstract][Full Text] [Related]
31. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation.
Mohty M; Bilger K; Jourdan E; Kuentz M; Michallet M; Bourhis JH; Milpied N; Sutton L; Jouet JP; Attal M; Bordigoni P; Cahn JY; Sadoun A; Ifrah N; Guyotat D; Faucher C; Fegueux N; Reiffers J; Maraninchi D; Blaise D
Leukemia; 2003 May; 17(5):869-75. PubMed ID: 12750699
[TBL] [Abstract][Full Text] [Related]
32. CD34 selected alloPBSCT and adoptive immunotherapy.
Knauf W; Fietz T; Schrezenmeier H; Thiel E
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S2-5. PubMed ID: 10933176
[TBL] [Abstract][Full Text] [Related]
33. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation.
Solomon SR; Nakamura R; Read EJ; Leitman SF; Carter C; Childs R; Dunbar CE; Young NS; Barrett AJ
Bone Marrow Transplant; 2003 May; 31(9):783-8. PubMed ID: 12732885
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303.
Keever-Taylor CA; Devine SM; Soiffer RJ; Mendizabal A; Carter S; Pasquini MC; Hari PN; Stein A; Lazarus HM; Linker C; Goldstein SC; Stadtmauer EA; O'Reilly RJ
Biol Blood Marrow Transplant; 2012 May; 18(5):690-7. PubMed ID: 21875505
[TBL] [Abstract][Full Text] [Related]
35. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
[TBL] [Abstract][Full Text] [Related]
36. High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation.
Passweg JR; Meyer-Monard S; Gregor M; Favre G; Heim D; Ebnoether M; Tichelli A; Gratwohl A
Bone Marrow Transplant; 2002 Sep; 30(5):267-71. PubMed ID: 12209347
[TBL] [Abstract][Full Text] [Related]
37. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.
Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Mordini N; Berisso G; Bregante S; Frassoni F; Sessarego M; Fugazza G; Di Stefano F; Pitto A; Bacigalupo A
Br J Haematol; 2000 Jun; 109(4):716-21. PubMed ID: 10929020
[TBL] [Abstract][Full Text] [Related]
38. Addition of a low fixed number of CD3+ cells to CD34-enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation.
Goerner M; Weber-Nordt R; Hoepfner S; Benner A; Luft T; Ho AD
J Hematother Stem Cell Res; 2003 Jun; 12(3):309-20. PubMed ID: 12857372
[TBL] [Abstract][Full Text] [Related]
39. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
40. Unrelated peripheral blood stem cell transplantation with 'megadoses' of purified CD34+ cells in three children with refractory severe aplastic anemia.
Schwinger W; Urban C; Lackner H; Kerbl R; Benesch M; Dornbusch HJ; Sovinz P; Schauenstein K; Schumm M; Handgretinger R
Bone Marrow Transplant; 2000 Mar; 25(5):513-7. PubMed ID: 10713628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
